356 related articles for article (PubMed ID: 34719665)
1. Identification of Potential Prognostic and Predictive Biomarkers for Immune-Checkpoint Inhibitor Response in Small Cell Lung Cancer.
Gao C; Gu X; Chen Y; Zhou M; Jiang F; Zheng S
Med Sci Monit; 2021 Nov; 27():e932275. PubMed ID: 34719665
[TBL] [Abstract][Full Text] [Related]
2. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
3. [Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors
of Small Cell Lung Cancer].
Yang Y; Wang Y
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):897-903. PubMed ID: 32773012
[TBL] [Abstract][Full Text] [Related]
4. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
[TBL] [Abstract][Full Text] [Related]
5. The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
Friedlaender A; Liu SV; Passaro A; Metro G; Banna G; Addeo A
Clin Lung Cancer; 2020 Nov; 21(6):e539-e543. PubMed ID: 32499210
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer.
Song Y; Sun Y; Sun T; Tang R
Comb Chem High Throughput Screen; 2020; 23(5):381-391. PubMed ID: 32264809
[TBL] [Abstract][Full Text] [Related]
8. Identification of Six Novel Prognostic Gene Signatures as Potential Biomarkers in Small Cell Lung Cancer.
Feng S; Zhang X; Gu X; Zhou M; Chen Y; Wang C
Comb Chem High Throughput Screen; 2023; 26(5):938-949. PubMed ID: 35490316
[TBL] [Abstract][Full Text] [Related]
9. Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer.
Henriques GT; Barbieri de Souza C; Aguiar PN
Immunotherapy; 2022 Mar; 14(4):249-257. PubMed ID: 35076285
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
11. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
13. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
[TBL] [Abstract][Full Text] [Related]
14. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
[TBL] [Abstract][Full Text] [Related]
15. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
Li L; Zhang Z; Hu Y
Medicine (Baltimore); 2021 Sep; 100(36):e27029. PubMed ID: 34516493
[TBL] [Abstract][Full Text] [Related]
16. [Immune Characteristics of Small Cell Lung Cancer].
Zhu Y; Wu S
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):889-896. PubMed ID: 33070515
[TBL] [Abstract][Full Text] [Related]
17. An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer.
Wang L; Wu P; Shen Z; Yu Q; Zhang Y; Ye F; Chen K; Zhao J
Int Immunopharmacol; 2023 Apr; 117():109827. PubMed ID: 36989973
[TBL] [Abstract][Full Text] [Related]
18. Identification of Immune Infiltration and Prognostic Biomarkers in Small Cell Lung Cancer Based on Bioinformatic Methods from 3 Studies.
Cao J; Yu C
Comb Chem High Throughput Screen; 2023; 26(3):507-516. PubMed ID: 35400336
[TBL] [Abstract][Full Text] [Related]
19. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
Front Immunol; 2021; 12():724443. PubMed ID: 34777341
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
Bianco A; D'Agnano V; Matera MG; Della Gravara L; Perrotta F; Rocco D
Expert Rev Respir Med; 2021 Nov; 15(11):1415-1425. PubMed ID: 34374626
[No Abstract] [Full Text] [Related]
[Next] [New Search]